INZY — Inozyme Pharma Share News
0.000.00%
Last trade - 00:00- $257.60m
- $219.11m
U.S. STOCKS ON THE MOVE-Carvana, Vistagen, Shoe Carnival
Inozyme Pharma falls on CEO retirement
Inozyme Pharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Inozyme Pharma Reports Full Year 2022 Financial Results And Provides Business Highlights
Brief: Inozyme Pharma Inc-Currently Maintains Modest Amount In Deposit Accounts, In The Low Single Digit Millions Of U.S. Dollars, With Silicon Valley Bank
Inozyme Pharma Inc expected to post a loss of 45 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-LabCorp, dental stocks, Community Health
U.S. STOCKS ON THE MOVE-Truist Financial, Microsoft, NRG Energy
U.S. STOCKS ON THE MOVE-Datadog, Crocs, Applied Therapeutics
Inozyme gains on positive data from trials of genetic disorder drug
Brief: Inozyme Pharma Reports Positive Topline Data From Ongoing Phase 1/2 Trials Of Inz-701
Brief: Inozyme Pharma Inc Company To Share Topline Data From Ongoing Phase 1/2 Trials Of Inz-701 In Enpp1 Deficiency And Abcc6 Deficiency At Virtual Event
Inozyme Pharma rises on complete enrolment for genetic disorder drug trials
Brief: Inozyme Pharma To Report Topline Data From Ongoing Phase 1/2 Clinical Trials In ENPP1 Deficiency, ABCC6 Deficiency In Q1 2023
Brief: Inozyme Pharma Reports Third Quarter Results
Inozyme Pharma Inc reports results for the quarter ended in September - Earnings Summary
Inozyme Pharma Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Inozyme Pharma Announces First Self-Administration Of INZ-701 In Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
Brief: Inozyme Pharma Announces Publication Of Comprehensive ENPP1 Variant Database